910 related articles for article (PubMed ID: 30081137)
1. Loss of activity of ceftazidime-avibactam due to MexAB-OprM efflux and overproduction of AmpC cephalosporinase in Pseudomonas aeruginosa isolated from patients suffering from cystic fibrosis.
Chalhoub H; Sáenz Y; Nichols WW; Tulkens PM; Van Bambeke F
Int J Antimicrob Agents; 2018 Nov; 52(5):697-701. PubMed ID: 30081137
[TBL] [Abstract][Full Text] [Related]
2. Role of efflux pumps: MexAB-OprM and MexXY(-OprA), AmpC cephalosporinase and OprD porin in non-metallo-β-lactamase producing Pseudomonas aeruginosa isolated from cystic fibrosis and burn patients.
Aghazadeh M; Hojabri Z; Mahdian R; Nahaei MR; Rahmati M; Hojabri T; Pirzadeh T; Pajand O
Infect Genet Evol; 2014 Jun; 24():187-92. PubMed ID: 24694825
[TBL] [Abstract][Full Text] [Related]
3. Phylogenetic analysis of resistance to ceftazidime/avibactam, ceftolozane/tazobactam and carbapenems in piperacillin/tazobactam-resistant Pseudomonas aeruginosa from cystic fibrosis patients.
Zamudio R; Hijazi K; Joshi C; Aitken E; Oggioni MR; Gould IM
Int J Antimicrob Agents; 2019 Jun; 53(6):774-780. PubMed ID: 30831233
[TBL] [Abstract][Full Text] [Related]
4. Combination of MexAB-OprM overexpression and mutations in efflux regulators, PBPs and chaperone proteins is responsible for ceftazidime/avibactam resistance in Pseudomonas aeruginosa clinical isolates from US hospitals.
Castanheira M; Doyle TB; Smith CJ; Mendes RE; Sader HS
J Antimicrob Chemother; 2019 Sep; 74(9):2588-2595. PubMed ID: 31225882
[TBL] [Abstract][Full Text] [Related]
5. In vitro activity of ceftazidime/avibactam against isolates of Pseudomonas aeruginosa collected in European countries: INFORM global surveillance 2012-15.
Kazmierczak KM; de Jonge BLM; Stone GG; Sahm DF
J Antimicrob Chemother; 2018 Oct; 73(10):2777-2781. PubMed ID: 30010951
[TBL] [Abstract][Full Text] [Related]
6. Mutation-driven β-lactam resistance mechanisms among contemporary ceftazidime-nonsusceptible Pseudomonas aeruginosa isolates from U.S. hospitals.
Castanheira M; Mills JC; Farrell DJ; Jones RN
Antimicrob Agents Chemother; 2014 Nov; 58(11):6844-50. PubMed ID: 25182652
[TBL] [Abstract][Full Text] [Related]
7. Overexpression of MexAB-OprM efflux pump in carbapenem-resistant Pseudomonas aeruginosa.
Pan YP; Xu YH; Wang ZX; Fang YP; Shen JL
Arch Microbiol; 2016 Aug; 198(6):565-71. PubMed ID: 27060003
[TBL] [Abstract][Full Text] [Related]
8. High-level resistance to meropenem in clinical isolates of Pseudomonas aeruginosa in the absence of carbapenemases: role of active efflux and porin alterations.
Chalhoub H; Sáenz Y; Rodriguez-Villalobos H; Denis O; Kahl BC; Tulkens PM; Van Bambeke F
Int J Antimicrob Agents; 2016 Dec; 48(6):740-743. PubMed ID: 28128097
[TBL] [Abstract][Full Text] [Related]
9. Multiple genotypic changes in hypersusceptible strains of Pseudomonas aeruginosa isolated from cystic fibrosis patients do not always correlate with the phenotype.
Wolter DJ; Black JA; Lister PD; Hanson ND
J Antimicrob Chemother; 2009 Aug; 64(2):294-300. PubMed ID: 19468029
[TBL] [Abstract][Full Text] [Related]
10. Avibactam confers susceptibility to a large proportion of ceftazidime-resistant Pseudomonas aeruginosa isolates recovered from cystic fibrosis patients.
Chalhoub H; Tunney M; Elborn JS; Vergison A; Denis O; Plésiat P; Kahl BC; Van Bambeke F; Tulkens PM
J Antimicrob Chemother; 2015 May; 70(5):1596-8. PubMed ID: 25587996
[No Abstract] [Full Text] [Related]
11. Ceftazidime/avibactam resistance is associated with PER-3-producing ST309 lineage in Chilean clinical isolates of non-carbapenemase producing
Soto KD; Alcalde-Rico M; Ugalde JA; Olivares-Pacheco J; Quiroz V; Brito B; Rivas LM; Munita JM; García PC; Wozniak A
Front Cell Infect Microbiol; 2024; 14():1410834. PubMed ID: 38903939
[TBL] [Abstract][Full Text] [Related]
12. Activity of ceftazidime/avibactam against problem Enterobacteriaceae and Pseudomonas aeruginosa in the UK, 2015-16.
Livermore DM; Meunier D; Hopkins KL; Doumith M; Hill R; Pike R; Staves P; Woodford N
J Antimicrob Chemother; 2018 Mar; 73(3):648-657. PubMed ID: 29228202
[TBL] [Abstract][Full Text] [Related]
13. Simultaneous and divergent evolution of resistance to cephalosporin/β-lactamase inhibitor combinations and imipenem/relebactam following ceftazidime/avibactam treatment of MDR Pseudomonas aeruginosa infections.
Alonso-García I; Vázquez-Ucha JC; Lasarte-Monterrubio C; González-Mayo E; Lada-Salvador P; Vela-Fernández R; Aja-Macaya P; Guijarro-Sánchez P; Rumbo-Feal S; Muíño-Andrade M; Fernández-González A; Martínez-Guitián M; Beceiro A; Rodríguez-Iglesias M; Oliver A; Arca-Suárez J; Galán-Sánchez F; Bou G
J Antimicrob Chemother; 2023 May; 78(5):1195-1200. PubMed ID: 36918743
[TBL] [Abstract][Full Text] [Related]
14.
Karlowsky JA; Kazmierczak KM; Bouchillon SK; de Jonge BLM; Stone GG; Sahm DF
Antimicrob Agents Chemother; 2018 Jul; 62(7):. PubMed ID: 29760124
[TBL] [Abstract][Full Text] [Related]
15. Expression of efflux pump MexAB-OprM and OprD of Pseudomonas aeruginosa strains isolated from clinical samples using qRT-PCR.
Arabestani MR; Rajabpour M; Yousefi Mashouf R; Alikhani MY; Mousavi SM
Arch Iran Med; 2015 Feb; 18(2):102-8. PubMed ID: 25644798
[TBL] [Abstract][Full Text] [Related]
16. OprD mutations and inactivation, expression of efflux pumps and AmpC, and metallo-β-lactamases in carbapenem-resistant Pseudomonas aeruginosa isolates from South Korea.
Lee JY; Ko KS
Int J Antimicrob Agents; 2012 Aug; 40(2):168-72. PubMed ID: 22633564
[TBL] [Abstract][Full Text] [Related]
17.
Karlowsky JA; Kazmierczak KM; Bouchillon SK; de Jonge BLM; Stone GG; Sahm DF
Antimicrob Agents Chemother; 2019 Apr; 63(4):. PubMed ID: 30670424
[TBL] [Abstract][Full Text] [Related]
18. Transcriptional Analysis of MexAB-OprM Efflux Pumps System of Pseudomonas aeruginosa and Its Role in Carbapenem Resistance in a Tertiary Referral Hospital in India.
Choudhury D; Das Talukdar A; Dutta Choudhury M; Maurya AP; Paul D; Dhar Chanda D; Chakravorty A; Bhattacharjee A
PLoS One; 2015; 10(7):e0133842. PubMed ID: 26221722
[TBL] [Abstract][Full Text] [Related]
19. Mutation-Driven Evolution of Pseudomonas aeruginosa in the Presence of either Ceftazidime or Ceftazidime-Avibactam.
Sanz-García F; Hernando-Amado S; Martínez JL
Antimicrob Agents Chemother; 2018 Oct; 62(10):. PubMed ID: 30082283
[TBL] [Abstract][Full Text] [Related]
20. [The roles of active efflux system overexpression and outer membrane protein OprD deficiency or loss in carbapenem resistance of Pseudomonas aeruginosa].
Yi MY; Wang PY; Huang HJ; Liu YC
Zhonghua Yi Xue Za Zhi; 2006 Feb; 86(7):457-62. PubMed ID: 16677571
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
